23 September 2016 - European regulators have issued approved Allergan's Truberzi, giving patients potential access to the first approved treatment for irritable bowel syndrome with diarrhoea.

The approval was based on data from two pivotal Phase III trials in which Truberzi (eluxadoline) showed a significant reduction in two of key symptoms linked with the condition - abdominal pain and diarrhoea - with sustained relief demonstrated over six months.

According to Allergan, eluxadoline was also generally well tolerated with the most common side effects of treatment being nausea, constipation, and abdominal pain.

Read Pharma Times article